Hunter, when looking at what we know I understand your comments.
But take the time and watch this video. It is about RAD but in general it applies to IMU and CHM too. Listen to the part regarding Lantheus and later on the reaction of the funds. Plus, can't remember Hopper appeared in person in a video answering instead of his CEOs.
The pieces seem to come together. Let's not get scared by the dilution, just go with it. If IMU would trade at 60c and you had $9000 you could by an extra 15000 shares. Now, the same money buys you 150000 shares. That way, whether IMU got sold for $10 one day ( 60c buy ) or $1 ( 6c buy ) you would end up with the same final amount.
Like the Lantheus deal, RAD does the treatment and Lantheus the imaging, Azer-Cel is licenced to another pharma for another application ( someone here found that out months ago ). Could become a similar scenario.
ATM the sp dominates our thinking and making conclusions, low sp - all is crap. But as RAD shows, that is not the case for the Hopper comps. Looks like the Amazon Boss quote can be applied here too: The sp is not the company, the company is not the sp.
When 7.5m + most likely another 7.5m in 6 months by Lantheus Pharma suddenly attract $62.5m by funds who last week wouldn't even speak out Hopper's name then LC's quote " Money follows the science " and the general quote " Small Money follows the Big Money " apply.
The next deal could come over at CHM, the CAR-T giant Kite / Gilead could have an eye on CDH17 and maybe Amgen could deal with IMU.
GLTA
IMU Price at posting:
5.6¢ Sentiment: Buy Disclosure: Held
(20min delay)